D4 dopamine receptor-mediated phospholipid methylation and its implications for mental illnesses such as schizophrenia

Molecular Psychiatry

Volumn 4, Issue 3, 1999, Pages 235-246

  Sharma, A ^a   Kramer, M L ^a,d   Wick, P F ^a   Liu, D ^a   Chari, S ^a   Shim, S ^a   Tan, W ^a   Ouellette, D ^a   Nagata, M ^a   DuRand, C J ^b   Kotb, M ^c   Deth, R C ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Univ of TN College of Medicine   (United States)

^d ARQULE INC   (United States)

Author keywords

De novo synthesis; Folic acid; G protein coupled; Membrane fluidity; Methionine; Phospholipid methylation; Purines; Receptors

Indexed keywords

CARBON 14; DOPAMINE; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENZYME; FORMIC ACID; GUANOSINE TRIPHOSPHATE; METHIONINE; PHOSPHOLIPID; TRITIUM;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; ISOTOPE LABELING; LYMPHOCYTE; MENTAL DISEASE; NEUROBLASTOMA CELL; NONHUMAN; PHOSPHOLIPID METHYLATION; PRIORITY JOURNAL; SCHIZOPHRENIA; SITE DIRECTED MUTAGENESIS;

EID: 0033010348     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000522     Document Type: Article

References (68)

1. 1 First MB (ed). Diagnostic and Statistical Manual of Mental Disorders (4th edn). Am Psychiatric Assoc: Washington, DC, 1994.
2. 2 Matthysse S. Antipsychotic drugs: a clue to the neuropathology of schizophrenia? Fed Proc 1973; 32: 200-205.
3. 3 Deutsch SI, Mastripaolo J, Schwartz BL, Rosse RB, Morihisa JM. A 'glutamatergic hypothesis' of schizophrenia: rationale for pharmacology with glycine. Clin Neuropharmacol 1989; 12: 1-13.
4. 4 Benes FM. Is there a neuroanatomic basis for schizophrenia? An old question revisited. The Neuroscientist 1995; 1: 104-115.
5. 5 Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis R. Linkage of a neurological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA 1997; 94: 587-592.
6. 4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350: 610-614.
7. 7 Seeman P, Guan H-G, Van Tol HHM. Dopamine D4 receptors are elevated in schizophrenia. Nature 1993; 365: 441-445.
8. 4 dopamine receptors in postmortem striatum from patients with schizophrenia. J Neuroscience 1995; 15: 2186-2191.
9. 9 Reynolds GP, Mason SL. Absence of detectable striatal dopamine D4 receptors in drug-treated schizophrenia. Eur J Pharmacol 1995; 281: R5-R6.
10. 4 dopamine receptor antagonist (L-745 870) in acutely psychotic inpatients with schizophrenia. Arch Gen Psychiatry 1997; 54: 567-572.
11. 4.4 receptor. Br J Pharmacol 1998; 124: 889-896.
12. 12 Van Tol HHM, Wu CM, Guan H-C, Ohara K, Bunzow JR, Civelli O et al. Multiple dopamine D4 receptor variants in the human population. Nature 1992; 358: 149-152.
13. 4 (DRD4) gene. Human Molec Genet 1993; 2: 767-773.
14. 14 Ebstein RP, Novick O, Umansky R, Priel B, Osher Y, Blaine D et al. Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of Novelty Seeking. Nature Genet 1996; 12: 78-80.
15. 15 Benjamin J, Li L, Patterson C, Greenberg BD, Murphy DL, Hamer DH. Population and familial association between the D4 dopamine receptor gene and measures of Novelty Seeking. Nature Genet 1996; 12: 81-84.
16. 16 Muramatsu T, Higuchi S, Murayama M, Matsushita S, Hayashida M. Association between alcoholism and the dopamine D4 receptor gene. J Med Genet 1996; 33: 113-115.
17. 17 LaHoste GJ, Swanson JM, Wigal SB, Glabe C, Wigal T, King N et al. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry 1996; 1: 121-124.
18. 4 receptor gene polymorphisms. Am J Psychiatry 1997; 154: 697-699.
19. 19 Park LC, Baldessarini RJ, Kety SS. Methionine effects on chronic schizophrenics. Arch Gen Psychiatry 1965; 12: 346-351.
20. 20 Kety SS. Biochemical theories of schizophrenia. Science 1959; 129: 1528-1532.
21. 21 Cohen SM, Nichols A, Wyatt R, Poulin W. The administration of methionine to chronic schizophrenic patients: a review of ten studies. Biol Psychiatry 1974; 8: 209-225.
22. 22 Sargent T, Kusubov N, Taylor SE, Budinger TF. Tracer kinetic evidence for abnormal methyl metabolism in schizophrenia. Biol Psychiatry 1992; 32: 1078-1090.
23. 23 Ismail L, Sargent T, Dobson TEL, Pollcove M. Altered metabolism of the methionine methyl group in the leukocytes of patients with schizophrenia. Biol Psychiatry 1978; 12: 649-660.
24. 24 Smythies JR, Alarcon RD, Morere DA, Monti JA, .Steele M, Tolbert LC et al. Abnormalities of one-carbon metabolism in psychiatric disorders: study of methionine adenosyltransferase kinetics and lipid composition of erythrocyte membranes. Biol Psychiatry 1986; 21: 1391-1398.
25. 25 Carl GF, Crews EL, Carmichael SM, Benesh FC, Smythies JR. Four enzymes of one-carbon metabolism in blood cells of schizophrenics. Biol Psychiatry 1978; 13: 773-776.
26. 26 Freeman JM, Finkelstein JD, Mudd SH. Folate-responsive homocystinuria and 'schizophrenia'. New Engl J Med 1975; 292: 491-496.
27. 27 Arinami T, Yamada N, Yamakawa K, Kobayashi N, Hamaguchi H, Toru M. Methylenetetrahydrofolate reductase variant and schizophrenia/depression. Am J Med Genet 1997; 74: 526-528.
28. 28 Regland B, Germgard T, Gottfries CG, Grenfeldt B, Koch-Schmidt AC. Homozygous thermolabile methylenetetrahydrofolate reductase in schizophrenia-like psychosis. J Neural Trans 1997; 104: 931-941.
29. 29 Le Fur C, Phan T, Canton T, Tur C, Uzan A. Evidence for a coupling between dopaminergic receptors and phospholipid methylation in mouse B lymphocytes. Life Sci 1981; 29: 2737-2749.
30. 30 Leprohon CE, Blusztajn JK, Wurtman RJ. Dopamine stimulation of phosphatidylcholine (lecithin) biosynthesis in rat brain neurons. Proc Natl Acad Sci USA 1983; 80: 2063-2066.
31. 31 De La Rosa J, Le Gros HL Jr, Geller AM, Koth M. Changes in the relative amount of subunits of methionine adenosyltransferase in human lymphocytes upon stimulation with a polyclonal T cell mitogen. J Biol Chem 1992; 267: 10699-10704.
32. 32 Sidhu A, Fishman PH. Identification and characterization of functional D1 dopamine receptors in a human neuroblastoma cell line. Biochem Biophys Res Comm 1990; 166: 574-579.
33. 4 receptor. J Med Chem 1996; 39: 1941-1942.
34. 34 Schlacter SK, Poel TJ, Lawson CF, Dinh DM, Lajiness ME, Rontero AG et al. Substituted 4-aminopiperdines having high in vitro affinity and selectivity for the human dopamine D4 receptor. Eur J Pharmacol 1997; 322: 283-286.
35. 4 receptors. J Neurochem 1994; 63: 62-65.
36. 36 Zorn SH, Jackson ER, Johnson CG, Lewis JM, Fliri A. CP-226,269 is a selective dopamine D4 receptor agonist. Soc Neurosci Abs 1997; 23: 685.
37. 37 Lanau F, Zenner M-T, Civelli O, Hartman D. Epinephrine and norepinephrine act as potent agonists at the recombinant human dopamine D4 receptor. J Neurochem 1997; 68: 804-812.
38. 38 Lombardini JB, Talalay P. Analogues of methionine as substrates and inhibitors of the methionine adenosyltransferase reaction. Mol Pharmacol 1970; 6: 481-499.
39. 39 Chiang PK, Richards HH, Cantoni GL. Homocysteine hydrolase: analogues of S-adenosyl-L-homocysteine as potential inhibitors. Mol Pharmacol 1977; 13: 939-947.
40. 12 in rats by nitrons oxide. Lancet 1978; ii: 1023-1024.
41. 41 Hirata F, Axelrod J. Phospholipid methylation and biological signal transmission. Science 1980; 209: 1082-1090.
42. 42 Farrens DL, Altenbach C, Yang K, Hubbell WL, Khorana G. Requirement for rigid-body motion of transmembrane helices for light activation of rhodopsin. Science 1996; 74: 768-769.
43. 1β adrenergic receptor by all amino acid substitutions at a single site: evidence for a region which constrains receptor activation. J Biol Chem 1992; 267: 1430-1433.
44. 2-adrenergic receptor. J Biol Chem 1993; 2618: 4625-4636.
45. 45 Harris RA, Schrooder F. Ethanol and the physical properties of brain membranes. Mol Pharmacol 1981; 20: 128-137.
46. A and glycine receptors. Nature 1997; 389: 385-389.
47. 47 Lovinger DM, White G, Weight FF. NMDA receptor-mediated synaptic excitation selectively inhibited by ethanol in hippocampal slice from adult rat. J Neurosci 1990; 10: 1372-1379.
48. 48 Franks NF, Lieb WR. Molecular and cellular mechanisms of general anaesthesia. Nature 1994; 367; 607-614.
49. 49 Casal HL, Mantsch HH. The thermotropic phase behavior of N-methylated dipalmiteylphosphatidylethanolamines. Biochim Biophys Acta 1983; 735: 387-396.
50. 50 Oak JN, Oldenhof J, Schoots O, Van Tol HHM. Screening for novel interactions with the polymorphic region of the human dopamine D4 receptor. Biochemistry 1998; 37: 15726-15736.
51. 51 Liu Y-F, Deth RC. Association of the dopamine D4 receptor with SH3 domain-containing proteins. J Biol Chem (under review).
52. 52 Mancillas J, Siggins GR, Bloom FE. Systemic ethanol: selective enhancement of responses to acetylcholine and somatostatin in the rat hippocampus. Science 1986; 231: 161-163.
53. 53 Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY. Clozapine and haloperidol modulate N-methyl-D-aspartate-and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 1997; 283: 226-234.
54. 54 Olney JW, Farber NB. Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity. J Clin Psychiatr 1994; 55 (Suppl B): 43-46.
55. 55 Malhotra AK, Adler CM, Kennison SD, Elman I, Pikar D, Breier A. Clozapine, blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol Psychiatry 1997; 42: 664-668.
56. 56 Yamamoto M, Mizuki Y, Suetsugi M, Ozawa Y, Ooyama M, Suzuki M. Effects of dopamine antagonists on changes in spontaneous EEG and locomotor activity in ketamine-treated rats. Pharmacol Biochem Behav 1997; 57: 361-365.
57. 57 Otmakhova NA, Lisman JE. Dopamine selectively inhibits the direct cortical pathway to the CA1 hippocampal region. J Neurosci 1998; 19: 1437-1445.
58. 58 Yu X-M, Askalan R, Keil GJ II, Salter M. NMDA channel regulation by channel-associated protein tyrosine kinase Src. Science 1997; 275: 674-678.
59. 59 Kornau H-C, Schenker LT, Kennedy MB, Seeburg PH. Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science 1995; 269: 1737-1740.
60. 60 Bondy B, Ackenheil M, Bizle W, Elbers R, Fröhler M. Catecholamines and their receptors in blood: evidence for alterations in schizophrenia. Biol Psychiatry 1984; 19: 1377-1393.
61. 61 Vile JM, Strange PG. D2-like dopamine receptors are not detectable on human peripheral blood lymphocytes. Biol Psychiatry 1996; 40: 881-885.
62. 62 Bondy B, de Jonge S, Pander S, Primbs J, Ackenheil M. Identification of dopamine D4 receptor mRNA in circulating human lymphocytes using nested polymerase chain reaction. J Immunol 1996; 71: 139-144.
63. 63 Karayiorgou M, Morris MA, Morrow B, Shprintzen RJ, Goldberg R, Borrow J at al. Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Proc. Natl Acad Sci USA 1995; 92: 7612-7616.
64. 64 Wang S, Sun C, Walczak CA, Ziegle JS, Kipps BR, Goldin LR et al. Evidence: for a susceptibility locus for schizophrenia on chromosome 6pter-p22. Nature Genet 1995; 10: 41-46.
65. 65 Rotrosen J, Wolkin A. Phospholipid and prostaglandin hypotheses of schizophrenia. In: Meltzer H (ed). Psychopharmacology: The Third Generation of Progress. Raven Press: New York, 1987, pp 759-764.
66. 4 dopamine receptor mRNAs in the primate cerebral cortex vs neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs. J Pharmacol Exp Ther 1997; 283: 939-946.
67. 4-like dopamine receptors. Neuropsychopharmacology 1997; 17: 186-196.
68. 68 O'Tauma LA, Phillips PC, Smith QR, Uno Y, Dannals RF, Wilson AA et al. L-Methionine uptake by human cerebral cortex: maturation from infancy to old age. J Nucl Med 1991; 32: 16-22.